ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

DOW JONES NEWSWIRES Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones. According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem. "We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development. Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million. A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful. Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months. Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
07/30/201414:45:16MARKET SNAPSHOT: S&P 500 Turns Positive As Fed Calms Rate-hike...
07/30/201413:15:33MARKET SNAPSHOT: U.S. Stocks Fall On Rate-hike Fears
07/30/201410:56:51MARKET SNAPSHOT: U.S. Stocks Pare Gains On Rate-hike Fears
07/30/201409:51:21MARKET SNAPSHOT: U.S. Stocks Open Higher After Strong GDP Report
07/30/201409:45:11U.S. Hot Stocks: Hot Stocks to Watch
07/30/201409:12:33MARKET SNAPSHOT: U.S. Stocks: Futures Add To Gains After GDP;...
07/30/201408:16:19MARKET SNAPSHOT: U.S. Markets: Futures Up With Twitter, GDP...
07/25/201406:03:01Bayer and Onyx Say Phase III Trial of Nexavar Breast Cancer Treatment...
07/02/201417:06:33Bind Therapeutics, Amgen End Collaboration on Targeted Cancer...
06/20/201421:35:07Atara Biotherapeutics, Backed by Carlos Slim, Files for IPO
06/09/201418:12:243M Finance Chief Departs for Amgen -- 2nd Update
06/09/201417:08:393M Finance Chief Departs for Amgen -- Update
05/12/201402:54:55AstraZeneca, Amgen Announce Positive Phase III Brodalumab Study
05/09/201418:31:12Amgen, AstraZeneca Announce Positive Results from Brodalumab...
04/22/201419:35:35Correction to Amgen Earnings Story
04/20/201406:17:33MARKET SNAPSHOT: Long View On Stocks Is Best During Weak Earnings...
04/11/201419:36:07Riding the Tech Roller Coaster
03/30/201408:44:49New Drugs to Lower Cholesterol Show Promise: Studies
03/26/201416:30:44Merck, Glaxo Hold Off on Help With Affordable Care Act Copays
03/17/201410:14:16Amgen Says Cholesterol Drug Study Meets Primary Endpoint

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad